Expert Interview
Discussing investigational therapies for Colorectal Cancer (CRC) including Zanzalintinib from Exelixis and Petosemtamab from Merus
Ticker(s): EXEL, MRUSInstitution: Mayo Clinic
- Oncologist at the Mayo Clinic with special interest in neuroendocrine tumors and gastrointestinal malignancies.
- Currently manages patients with colon cancer, esophageal cancer, gallbladder cancer, liver cancer, neuroendocrine tumors, pancreatic cancer, rectal cancer, small bowel cancer, stomach cancer.
- Active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents for neuroendocrine and gastrointestinal cancers.
How many CRC patients do you manage?
How enthusiastic are you about zanzalintinib?
Added By: wilson_adminHow enthusiastic are you about petosemtamab?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
